Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2009

View Archived Issues

Vasopressin V2 receptor antagonist shows potential for treatment of ascites in cirrhotic patients

ITMN-191 and R-7128 combination reduces development of HCV resistance

Potent dual HCV/HIV replication inhibitors RO-0622, RO-9187 identified

Novel compounds for the treatment of pain discovered by Daiichi Sankyo

Researchers describe first bivalent humanized IgG1 antibody directed against human c-Met

Gene therapy Ad-IFNalpha/Syn3 safe and well tolerated in phase I study in bladder cancer

Topical AS-101 shows promise in treating psoriasis

Skin penetration of antifungal agents increased with the addition of NB-002

Novavax initiates enrollment in phase II clinical trial of VLP seasonal influenza vaccine

Replikins begins production of synthetic H1N1 swine flu vaccine

Merck initiates phase III SETTLE trial of safinamide in Parkinson's disease

AcelRx commences phase II clinical trial of ARX-01 Sufentanil NanoTab PCA System

Nymox begins enrollment into second phase III clinical trial of NX-1207 for BPH

Clavis reports preclinical data that differentiate CP-4200 from current standard cancer therapy

BioInvent reports phase I results for its therapeutic antibody BI-204

Anthera reports favorable results from phase II clinical trial of varespladib in ACS

Pierre Fabre initiates clinical trials of a pediatric beta-blocker for infantile hemangioma

D-Pharm submits IND and SPA to FDA for phase III trial of DP-b99 in acute stroke

Enzon establishes recommended dose of cancer drug PEG-SN38 for phase II studies

Intravitreal ARC-1905 combined with ranibizumab shows no toxicity in phase I trial

Pharmalucia claims novel compounds for the treatment of bacterial infections

Korea Research Institute of Chemical Technology describes novel inhibitors of ischemic cell death

Amsterdam Molecular treats first patient in preregistration clinical trial of Glybera

Oxygen Biotherapeutics files orphan drug application with FDA for Oxycyte

FDA grants priority review to Wyeth's BLA for pneumococcal vaccine Prevnar 13

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...